<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02788747</url>
  </required_header>
  <id_info>
    <org_study_id>SPIHF-201</org_study_id>
    <secondary_id>2014-005724-10</secondary_id>
    <nct_id>NCT02788747</nct_id>
  </id_info>
  <brief_title>Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects
      with stable heart failure (HF) with reduced ejection fraction (HFrEF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects
      with stable heart failure (HF) with reduced ejection fraction (HFrEF). After completing the
      Screening period, a total of 71 subjects were randomized, in a 1:1:1 ratio, to receive either
      placebo, 4 mg elamipretide, or 40 mg elamipretide once daily for 28 consecutive days.

      Each treatment group went through 3 distinct periods: Screening, Treatment, and Follow up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Left Ventricular End Systolic Volume (ml)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in left ventricular end systolic volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction (% of Blood Volume)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Left Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Diastolic Volume (ml) as Measured by MRI</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change from baseline in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Stroke Volume (ml)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Left Ventricular Stroke Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Cardiac Output (L/Min)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Left Ventricular Cardiac Output as measured by L/min from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Myocardial Mass (g)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Left Ventricular Myocardial Mass as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Right Ventricular End Systolic Volume (mL)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Right Ventricular End Systolic Volume as measured by mL from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Right Ventricular End Diastolic Volume (mL)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Right Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Right Ventricular Ejection Fraction (% Blood Volume)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Right Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Early and Late Mitral Inflow Velocity Ratio</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Early and Late Mitral Inflow Velocity Ratio from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio (E/e')</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio as measured by E/e' from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Atrial Volume (mL)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Left Atrial Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Global Longitudinal Strain Assessment (%)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Left Ventricular Global Longitudinal Strain Assessment as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Diastolic Volume (mL) as Measured by Echocardiography</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Systolic Volume (mL) as Measured by Echocardiography</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Left Ventricular End Systolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biplane Ejection Fraction (mL)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Biplane Ejection Fraction as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Mass Assessment (g)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Left Ventricular Mass Assessment as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tricuspid Regurgitation Severity Assessment (cmÂ²)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Tricuspid Regurgitation Severity Assessment as measured by cm from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Right Ventricular Fractional Area (%)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change Right Ventricular Fractional Area in as measured by percentage from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Right Ventricular Systolic Pressure (mmHg)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Change in Right Ventricular Systolic Pressure as measured by mmHg from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mitral Regurgitation Severity (cmÂ²)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Change in Mitral Regurgitation Severity as measured by cmÂ² from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>4 mg elamipretide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg elamipretide once daily for 28 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg elamipretide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg elamipretide once daily for 28 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 28 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg elamipretide</intervention_name>
    <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
    <arm_group_label>4 mg elamipretide</arm_group_label>
    <other_name>MTP-131</other_name>
    <other_name>Bendavia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg elamipretide</intervention_name>
    <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
    <arm_group_label>40 mg elamipretide</arm_group_label>
    <other_name>MTP-131</other_name>
    <other_name>Bendavia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide signed informed consent form (ICF) prior to participation
             in any study-related procedures.

          -  Age â¥40 and â¤80 years.

          -  A known history of chronic ischemic or non-ischemic cardiomyopathy of at least 6
             months duration from the time of the initial diagnosis.

          -  Receiving heart failure (HF) treatment, including, but not limited to, angiotensin
             converting enzyme inhibitors (ACEI) and/or angiotensin receptor blockers (ARB), and an
             evidence-based beta blocker for the treatment of HF. Subjects who cannot tolerate ACEI
             or ARB due to reduced renal function or hypotension are eligible. Subjects may be
             receiving aldosterone antagonists, but this is not a requirement for the study.

          -  HF is considered to be stable in the judgment of the Investigator AND doses of HF
             treatment have been stable for at least 1 month prior to the Screening Visit.

          -  In normal sinus rhythm (electrocardiogram documented) at Screening and Day 1 and no
             history of atrial fibrillation in the past 12 months

          -  No hospitalization related to HF within 1 month prior to the Screening Visit.

          -  Left Ventricular Ejection Fraction (LVEF) â¤ 40% by 2-D echocardiography at Screening.

          -  At least 3 viable segments (hyperenhancement â¤ 25%) by a qualifying delayed
             gadolinium-enhanced cardiac MRI examination at Screening (confirmed by independent
             core lab).

          -  Women of childbearing potential must agree to use 1 of the following methods of birth
             control from the date they sign the ICF until two months after the last dose of study
             medication:

               -  Abstinence, maintenance of monogamous relationship with a male partner who has
                  been surgically sterilized by vasectomy, or barrier method AND either hormonal
                  contraception or an intrauterine device or system.

        Exclusion Criteria:

          -  History of any concurrent medical condition which, in the opinion of the Investigator,
             significantly increased the potential risks associated with administration of study
             medication or any other aspect of study participation.

          -  Any contraindication to MRI scanning.

          -  Left ventricular end diastolic dimension (LVEDD) indexed to Body Surface Area is &gt; 45
             mm/m2.

          -  Coronary or peripheral revascularization procedures, valvular procedures, OR any major
             surgical procedure within 3 months prior to the Screening Visit.

          -  Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 3 months
             prior to the Screening Visit.

          -  Obstructive or restrictive cardiomyopathy, infiltrative diseases of the myocardium
             (e.g., amyloid, sarcoid, etc.) myocarditis, or reductions in LV function thought to be
             secondary primarily to valvular heart disease, prior cardiac valve surgery or known
             aortic stenosis.

          -  The presence or anticipated placement of any pacemaker, implantable cardioverter
             defibrillator (ICD), or cardiac resynchronization therapy (CRT) devices during the
             ensuing 6-week study period.

          -  Presence of second degree or advanced heart block.

          -  Uncontrolled hypertension defined as a systolic blood pressure &gt; 160 mmHg or a
             diastolic blood pressure &gt; 110 mmHg on at least two consecutive readings.

          -  Presence of any left ventricular thrombus, pericardial disease, uncorrected thyroid
             disease or a dyskinetic left ventricular aneurysm.

          -  History of cancer that causes symptoms, disabilities, or is likely to lead to
             hospitalization or treatment in the next 12 months.

          -  Currently receiving treatment with chemotherapeutic agents or immunosuppressant agents
             or has received prior radiation therapy to the chest.

          -  Liver enzymes (alanine aminotransferase [ALT] AND/OR aspartate. aminotransferase
             [AST]) elevation &gt; 3 times the upper limit of normal (ULN).

          -  Total bilirubin &gt; 1.5 times ULN in the absence of Gilbert's Syndrome.

          -  Bleeding diathesis or any known blood dyscrasia.

          -  Anemia, defined as hemoglobin &lt; 9 g/dL or planned blood transfusions in the next 6
             weeks.

          -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min, using the Modification of
             Diet in Renal Disease (MDRD) Study equation.

          -  History of hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection,
             or diagnosis of immunodeficiency.

          -  Known active drug or alcohol abuse within 1 year of the Screening Visit. Alcohol abuse
             is defined as 15 or more drinks for men per week or 8 or more for women.

          -  Recipient of any investigational drugs, stem cell or gene therapies, or devices OR
             participation in another clinical trial, within 3 months prior to the Screening Visit.

          -  Female subjects who are pregnant, planning to become pregnant, or lactating.

          -  Requiring any change in doses of cardiovascular medication (including diuretics) in
             order to control worsening of HF symptoms.

          -  Known allergy to gadolinium.

          -  Currently receiving treatment with therapeutic doses of anticoagulants. Antiplatelet
             therapy used to prevent cardiovascular disease (primary prevention) or to treat
             chronic disease (secondary prevention) is permitted.

          -  Currently receiving treatment with sacubitril/valsartan or trimetazidine.

          -  Hyponatremia defined as plasma Na+ level &lt;125 mEq/L (UK only).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerasimos Filippatos, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Athens, School of Medicine, Athens, Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O. Papa Giovanni XXIII Cardiologia 1, Torre 5</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili di Brescia Cardiologia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Brotzu Cardiologia</name>
      <address>
        <city>Cagliari</city>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino U.O. Scompenso, Cardiologia Clinica e Cardiologia Riabilitativa</name>
      <address>
        <city>Milano</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda Ca' Granda SC Cardiologia 2</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiologia clinica, UnitÃ  dello Scompenso e Terapia intensive Reparto Carlo Magno, Faggi Policlinico di Monza</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. Cardiotoracovascolare: Cardiologia Fondazione IRCCS Policlinico San Matteo Pad. Nuovo Ospedale &quot;DEA&quot; Degenza: PIANO +3 Ambulatori: P.T. e P+3</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di SanitÃ  Pubblica</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Hospital, Department of Cardiology</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anthonius Ziekenhuis, Cardiology Department</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Twee Steden Hospital (ETZ), Department of Cardiology</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuis Zutphen, Department of Cardiology</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <zip>DDI 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Harvey Heart Centre CRC, (Barts Health NHS Trust)</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <results_first_submitted>April 6, 2020</results_first_submitted>
  <results_first_submitted_qc>April 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 22, 2020</results_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02788747/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02788747/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>4 mg Elamipretide</title>
          <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
        </group>
        <group group_id="P2">
          <title>40 mg Elamipretide</title>
          <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 22 subjects in the 4 mg group, 1 subject (1.4%) discontinued from the study due to an AE. One of the subjects randomized to 4mg elamipretide arm was treated with 40mg elamipretide.</population>
      <group_list>
        <group group_id="B1">
          <title>4 mg Elamipretide</title>
          <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
        </group>
        <group group_id="B2">
          <title>40 mg Elamipretide</title>
          <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="71"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.3" spread="10.76"/>
                    <measurement group_id="B2" value="62.6" spread="9.63"/>
                    <measurement group_id="B3" value="66.8" spread="9.07"/>
                    <measurement group_id="B4" value="64.8" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left ventricular end systolic volume</title>
          <description>Left ventricular end systolic volume (ml) as measured by MRI</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.0" spread="38.45"/>
                    <measurement group_id="B2" value="79.6" spread="21.54"/>
                    <measurement group_id="B3" value="77.7" spread="38.58"/>
                    <measurement group_id="B4" value="81.3" spread="33.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Left Ventricular End Systolic Volume (ml)</title>
        <description>Change in left ventricular end systolic volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom left ventricular end systolic volume was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>4 mg elamipretide: subcutaneous injection administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>40 mg elamipretide: subcutaneous injection administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo: subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Systolic Volume (ml)</title>
          <description>Change in left ventricular end systolic volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
          <population>All participants for whom left ventricular end systolic volume was measured at baseline and Week 4</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="6.50"/>
                    <measurement group_id="O2" value="-1.2" spread="9.04"/>
                    <measurement group_id="O3" value="-3.8" spread="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Ejection Fraction (% of Blood Volume)</title>
        <description>Change in Left Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for Left Ventricular Ejection Fraction was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Ejection Fraction (% of Blood Volume)</title>
          <description>Change in Left Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
          <population>All participants for Left Ventricular Ejection Fraction was measured at baseline and Week 4</population>
          <units>percentage of blood volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="2.43"/>
                    <measurement group_id="O2" value="1.5" spread="2.82"/>
                    <measurement group_id="O3" value="2.3" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End Diastolic Volume (ml) as Measured by MRI</title>
        <description>Change from baseline in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Left Ventricular End Diastolic Volume was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Diastolic Volume (ml) as Measured by MRI</title>
          <description>Change from baseline in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
          <population>All participants for whom Left Ventricular End Diastolic Volume was measured at baseline and Week 4</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="9.50"/>
                    <measurement group_id="O2" value="0.5" spread="11.96"/>
                    <measurement group_id="O3" value="-2.2" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Stroke Volume (ml)</title>
        <description>Change in Left Ventricular Stroke Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Left Ventricular Stroke Volume was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Stroke Volume (ml)</title>
          <description>Change in Left Ventricular Stroke Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
          <population>All participants for whom Left Ventricular Stroke Volume was measured at baseline and Week 4</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="9.23"/>
                    <measurement group_id="O2" value="3.7" spread="9.36"/>
                    <measurement group_id="O3" value="3.0" spread="13.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Cardiac Output (L/Min)</title>
        <description>Change in Left Ventricular Cardiac Output as measured by L/min from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Left Ventricular Cardiac Output was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Cardiac Output (L/Min)</title>
          <description>Change in Left Ventricular Cardiac Output as measured by L/min from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
          <population>All participants for whom Left Ventricular Cardiac Output was measured at baseline and Week 4</population>
          <units>L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="1.264"/>
                    <measurement group_id="O2" value="-0.01" spread="1.004"/>
                    <measurement group_id="O3" value="0.27" spread="0.860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Myocardial Mass (g)</title>
        <description>Change in Left Ventricular Myocardial Mass as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Left Ventricular Myocardial Mass was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Myocardial Mass (g)</title>
          <description>Change in Left Ventricular Myocardial Mass as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
          <population>All participants for whom Left Ventricular Myocardial Mass was measured at baseline and Week 4</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.82"/>
                    <measurement group_id="O2" value="-0.4" spread="2.78"/>
                    <measurement group_id="O3" value="-0.0" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Right Ventricular End Systolic Volume (mL)</title>
        <description>Change in Right Ventricular End Systolic Volume as measured by mL from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Right Ventricular End Systolic Volume was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Right Ventricular End Systolic Volume (mL)</title>
          <description>Change in Right Ventricular End Systolic Volume as measured by mL from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
          <population>All participants for whom Right Ventricular End Systolic Volume was measured at baseline and Week 4</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="4.21"/>
                    <measurement group_id="O2" value="-0.8" spread="4.94"/>
                    <measurement group_id="O3" value="-0.6" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Right Ventricular End Diastolic Volume (mL)</title>
        <description>Change in Right Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Right Ventricular End Diastolic Volume was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Right Ventricular End Diastolic Volume (mL)</title>
          <description>Change in Right Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
          <population>All participants for whom Right Ventricular End Diastolic Volume was measured at baseline and Week 4</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="9.70"/>
                    <measurement group_id="O2" value="-1.2" spread="10.72"/>
                    <measurement group_id="O3" value="-0.0" spread="7.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Right Ventricular Ejection Fraction (% Blood Volume)</title>
        <description>Change in Right Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Right Ventricular Ejection Fraction was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Right Ventricular Ejection Fraction (% Blood Volume)</title>
          <description>Change in Right Ventricular Ejection Fraction as measured by percentage of blood volume from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by MRI.</description>
          <population>All participants for whom Right Ventricular Ejection Fraction was measured at baseline and Week 4</population>
          <units>percentage of blood volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="3.05"/>
                    <measurement group_id="O2" value="0.4" spread="2.10"/>
                    <measurement group_id="O3" value="1.2" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Early and Late Mitral Inflow Velocity Ratio</title>
        <description>Change in Early and Late Mitral Inflow Velocity Ratio from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Early and Late Mitral Inflow Velocity Ratio was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Early and Late Mitral Inflow Velocity Ratio</title>
          <description>Change in Early and Late Mitral Inflow Velocity Ratio from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Early and Late Mitral Inflow Velocity Ratio was measured at baseline and Week 4</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.185"/>
                    <measurement group_id="O2" value="-0.03" spread="0.329"/>
                    <measurement group_id="O3" value="-0.07" spread="0.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio (E/e')</title>
        <description>Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio as measured by E/e' from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio (E/e')</title>
          <description>Change in Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio as measured by E/e' from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Early Mitral Inflow Velocity and Mitral Annular Early Diastolic Velocity Ratio was measured at baseline and Week 4</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="3.244"/>
                    <measurement group_id="O2" value="0.47" spread="4.359"/>
                    <measurement group_id="O3" value="-0.20" spread="4.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Atrial Volume (mL)</title>
        <description>Change in Left Atrial Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Left Atrial Volume was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Atrial Volume (mL)</title>
          <description>Change in Left Atrial Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Left Atrial Volume was measured at baseline and Week 4</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="6.85"/>
                    <measurement group_id="O2" value="-0.2" spread="4.41"/>
                    <measurement group_id="O3" value="1.6" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Global Longitudinal Strain Assessment (%)</title>
        <description>Change in Left Ventricular Global Longitudinal Strain Assessment as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Left Ventricular Global Longitudinal Strain Assessment was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Global Longitudinal Strain Assessment (%)</title>
          <description>Change in Left Ventricular Global Longitudinal Strain Assessment as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Left Ventricular Global Longitudinal Strain Assessment was measured at baseline and Week 4</population>
          <units>percentage of myocardial length change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="1.993"/>
                    <measurement group_id="O2" value="-1.50" spread="2.721"/>
                    <measurement group_id="O3" value="-1.46" spread="2.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End Diastolic Volume (mL) as Measured by Echocardiography</title>
        <description>Change in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Left Ventricular End Diastolic Volume was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Diastolic Volume (mL) as Measured by Echocardiography</title>
          <description>Change in Left Ventricular End Diastolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Left Ventricular End Diastolic Volume was measured at baseline and Week 4</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="16.29"/>
                    <measurement group_id="O2" value="1.6" spread="13.68"/>
                    <measurement group_id="O3" value="2.0" spread="15.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End Systolic Volume (mL) as Measured by Echocardiography</title>
        <description>Change in Left Ventricular End Systolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Left Ventricular End Systolic Volume was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Systolic Volume (mL) as Measured by Echocardiography</title>
          <description>Change in Left Ventricular End Systolic Volume as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Left Ventricular End Systolic Volume was measured at baseline and Week 4</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="11.59"/>
                    <measurement group_id="O2" value="-0.5" spread="7.91"/>
                    <measurement group_id="O3" value="0.6" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Biplane Ejection Fraction (mL)</title>
        <description>Change in Biplane Ejection Fraction as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Biplane Ejection Fraction was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biplane Ejection Fraction (mL)</title>
          <description>Change in Biplane Ejection Fraction as measured by ml from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Biplane Ejection Fraction was measured at baseline and Week 4</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.94"/>
                    <measurement group_id="O2" value="2.0" spread="2.82"/>
                    <measurement group_id="O3" value="1.5" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Mass Assessment (g)</title>
        <description>Change in Left Ventricular Mass Assessment as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Left Ventricular Mass was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Mass Assessment (g)</title>
          <description>Change in Left Ventricular Mass Assessment as measured by grams from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Left Ventricular Mass was measured at baseline and Week 4</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="18.26"/>
                    <measurement group_id="O2" value="-4.2" spread="18.55"/>
                    <measurement group_id="O3" value="-0.7" spread="21.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tricuspid Regurgitation Severity Assessment (cmÂ²)</title>
        <description>Change in Tricuspid Regurgitation Severity Assessment as measured by cm from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Tricuspid Regurgitation Severity Assessment was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tricuspid Regurgitation Severity Assessment (cmÂ²)</title>
          <description>Change in Tricuspid Regurgitation Severity Assessment as measured by cm from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Tricuspid Regurgitation Severity Assessment was measured at baseline and Week 4</population>
          <units>cmÂ²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="1.334"/>
                    <measurement group_id="O2" value="0.25" spread="1.336"/>
                    <measurement group_id="O3" value="-0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Right Ventricular Fractional Area (%)</title>
        <description>Change Right Ventricular Fractional Area in as measured by percentage from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Right Ventricular Fractional Area was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Right Ventricular Fractional Area (%)</title>
          <description>Change Right Ventricular Fractional Area in as measured by percentage from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Right Ventricular Fractional Area was measured at baseline and Week 4</population>
          <units>percentage of area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="10.82"/>
                    <measurement group_id="O2" value="0.1" spread="8.79"/>
                    <measurement group_id="O3" value="0.9" spread="8.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Right Ventricular Systolic Pressure (mmHg)</title>
        <description>Change in Change in Right Ventricular Systolic Pressure as measured by mmHg from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Right Ventricular Systolic Pressure was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Right Ventricular Systolic Pressure (mmHg)</title>
          <description>Change in Change in Right Ventricular Systolic Pressure as measured by mmHg from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Right Ventricular Systolic Pressure was measured at baseline and Week 4</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="16.19"/>
                    <measurement group_id="O2" value="-1.5" spread="6.63"/>
                    <measurement group_id="O3" value="-7.0" spread="25.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mitral Regurgitation Severity (cmÂ²)</title>
        <description>Change in Mitral Regurgitation Severity as measured by cmÂ² from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>All participants for whom Mitral Regurgitation Severity was measured at baseline and Week 4</population>
        <group_list>
          <group group_id="O1">
            <title>4 mg Elamipretide</title>
            <description>Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O2">
            <title>40 mg Elamipretide</title>
            <description>Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mitral Regurgitation Severity (cmÂ²)</title>
          <description>Change in Mitral Regurgitation Severity as measured by cmÂ² from baseline (last assessment prior to start of study) to Week 4 (end of treatment visit) as assessed by echocardiography.</description>
          <population>All participants for whom Mitral Regurgitation Severity was measured at baseline and Week 4</population>
          <units>cmÂ²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="2.668"/>
                    <measurement group_id="O2" value="-0.71" spread="2.200"/>
                    <measurement group_id="O3" value="-0.73" spread="1.834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks (The AE reporting period began when the subject signed the ICF and continued through the clinical studyâs post treatment follow-up period, defined as 14 days after last administration of study medication.)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>4 mg Elamipretide</title>
          <description>4 mg elamipretide: subcutaneous injection administered once daily for 28 consecutive days</description>
        </group>
        <group group_id="E2">
          <title>40 mg Elamipretide</title>
          <description>40 mg elamipretide: subcutaneous injection administered once daily for 28 consecutive days</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo: subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased Blood bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eosinphil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Albuminiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jim Carr PharmD Chief Clinical Development Officer</name_or_title>
      <organization>Stealth BioTherapeutics Inc.</organization>
      <phone>617-600-6888</phone>
      <email>jim.carr@stealthbt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

